BioCentury
ARTICLE | Financial News

EpimAb raises $25M in series A

April 25, 2017 4:33 AM UTC

EpimAb Biotherapeutics Inc. (Shanghai, China) raised $25 million in a series A round led by Oriza Seed Capital. Also participating were Decheng Capital, 3E Bioventures Capital and Trend Investment Group.

EpimAb is developing bispecific antibodies for immuno-oncology using its Fabs-In-Tandem Immunoglobulin (FIT-Ig) technology. The antibodies are designed to be more potent and stable, less immunogenic and easier to manufacture than those made by competing platforms (see BioCentury, Feb. 3). ...

BCIQ Company Profiles

EpimAb Biotherapeutics Inc.